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Netherlands Cancer Institute, Head and Neck Oncology & Surgery, Amsterdam, The Netherlands Purpose or Objective: Head and neck cancer patients treated with chemoradiation are at risk for developing trismus (reduced mouth opening). Trismus is often a persisting side-effect and difficult to manage. It impairs eating, speech and oral hygiene, affecting quality of life.
Although several studies identified the masseter muscle (MM) as one of the main organs at risk, currently this structure is rarely considered during treatment planning. Prospective studies for chemoradiation are lacking. The aim of our study was to quantify the relationship between radiation dose to the MM and development of radiation-induced trismus in an IMRT-VMAT population.
Material and Methods:
The 93 patients in this study participated in a prospective preventive exercise program to preserve oral functioning between 2006-2013. All received concomitant high-dose chemotherapy during VMAT-or IMRTradiotherapy (70 Gy in 35 fractions). Tumor locations were mainly oropharynx (37%) and hypopharynx (33%). Maximum interincisor mouth opening was measured before and approximately 10 weeks after the end of treatment. Bilateral delineations of the MM were available from 2 retrospective studies. Patients were excluded if trismus was present at baseline, or if gross tumor infiltration of the MM was present on CT evaluation. Evaluated outcomes were trismus (mouth opening ≤ 35 mm) and decrease in mouth opening. Logistic regression (using maximum likelihood) was performed.
Results:
At the first evaluation, 6-12 weeks post-treatment, fourteen patients had developed radiation-induced trismus (15%). On average, mouth opening decreased with 4.1 mm, or 8.2 % relative to baseline. Mean dose to the ipsilateral MM was a stronger predictor for trismus than mean dose to the contralateral MM, as indicated by the lowest -2 log likelihood (Table 1) . Figure 1A shows the correlation between the ipsilateral mean masseter dose and the relative decrease in mouth opening, with trismus cases indicated in red. No trismus cases were observed in 33 patients (35%) with a mean dose to the ipsilateral MM < 20 Gy. The risk of trismus in the other 60 patients (65%) increased with higher mean doses to the ipsilateral MM. Figure 1B shows the fitted NTCP curve as a function of the mean dose, with a TD50 of 55 Gy. The actual incidence (with 1 SE) of trismus cases within 5 dose bins is indicated as well, showing a good correspondence with the NTCP fit with a relatively large uncertainty in the dose area > 50 Gy. Patients with tumors located in the oropharynx were at highest risk.
Conclusion:
The risk of trismus can be established with the mean dose to the ipsilateral masseter muscle. The majority of head and neck cancer patients could benefit from dose reduction to the masseter muscles to prevent trismus, especially patients with a mean dose to the ipsilateral masseter > 20 Gy. Further development of a NTCP model could identify dose objectives to guide treatment planning.
PO-0636
Safety profile support efficacy of gingival clonidine tablet to prevent severe oral mucositis in HNC Y. Tao 1 Institut Gustave Roussy, Département de Radiotherapie, Villejuif, France S298 ESTRO 35 2016 ______________________________________________________________________________________________________ studies, topical clonidine shown activity in reducing NF-κB activation and incidence of severe OM (SOM). In a randomized double blind, placebo-controlled study, a novel mucoadhesive buccal tablet (MBT) containing clonidine reduced the incidence of SOM in HNC patients being treated with CRT. We now report overall survival (OS), tolerability and systemic exposure of clonidine of study subjects.
Material and Methods:
Clonidine MBT 50µg (n= 56), 100µg (n= 65) or matching placebo (n= 62) were applied to the gum once daily 1-3 days prior to RT and then daily until the end of CRT (1.8-2.2 Gy/d, 5 times/week combined with a platinum based CT). AEs, vital signs and gingival tolerance by Silness-Loe index (global score from 0 to 9) were assessed twice a week; xerostomia and sedation (visual scale from 0 to 10) were evaluated once a week. Blood and saliva samples for clonidine levels were collected Q2 weeks. OS data will be collected until 2 years after last patient last visit. Patients received a median cumulative radiation dose of 66 Gy [min: 4; max: 78] . SOM was reported in 60% [95%CI: 47%; 72%] of placebo patients, 43% [95%CI: 29%; 57%] in clonidine 50µg MBT (p=0.063) and 48 % [95%CI: 35%; 61%] in clonidine 100µg MBT (p=0.169) .
Results:
All grade AE incidence was 91% in clonidine MBT groups and 98% in placebo group (p<0.10). No difference in heart rate and blood pressure was reported between groups. Reversible hypotension AEs were reported in 7% clonidine MBT 50µg patients, 6% clonidine MBT 100μg and 2% placebotreated patients (p= ns). Sedation score slightly increased in all groups between week 1 and week 6 (overall from 1.5 ± 2.3 to 3.0 ±2.3) and was similar between groups (p = ns). Xerostomia grade ≥ 2 increased to 41% in clonidine MBT 50µg, 31% in clonidine MBT 100µg and 42% in placebo patients (p= ns). The mean plasma/saliva concentrations of clonidine were 0.087/154.2ng/mL in clonidine MBT 50µg and 0.134/301.1 ng/mL in clonidine MBT 100µg. With a median follow-up of 15 months, the median 1year-OS of 89.3% [95%CI: 73.9; 95.8] placebo and 89.7% [95%CI: 80.4; 94.8] clonidine MBT.
Conclusion:
Clonidine MBT daily applied to the gum throughout CRT reduced the incidence of SOM and was well tolerated in HNC patients undergoing postoperative CRT. No significant systemic effects of clonidine were reported in the phase 2 study probably due to its low systemic levels.
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